Abiopharma

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

New Form 6-K - Can-Fite BioPharma Ltd. Filed: 2025-06-16 AccNo: 0001213900-25-054510 Size: 23 KB

Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial

Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston

New Form 4 - Immuneering Corp Filed: 2025-06-16 AccNo: 0001790340-25-000067 Size: 5 KB

Psychemedics Releases 2025 Workforce Insights Report

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

UTHR: Notification

New Form 4 - Immuneering Corp Filed: 2025-06-16 AccNo: 0001790340-25-000065 Size: 5 KB

New Form 4 - UNITED THERAPEUTICS Corp Filed: 2025-06-16 AccNo: 0001562180-25-004834 Size: 20 KB

New Form 8-K - Immuneering Corp Filed: 2025-06-16 AccNo: 0001790340-25-000063 Size: 153 KB Item 5.07: Submission of Matters to a Vote of Security Holders

New Form S-1 - SeaStar Medical Holding Corp Filed: 2025-06-16 AccNo: 0001213900-25-054502 Size: 14 MB

New Form 8-K - Onconetix, Inc. Filed: 2025-06-16 AccNo: 0001213900-25-054501 Size: 200 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Ecolab Life Sciences推出新型生物製程純化樹脂，以提升生產效率

New Form 8-K - SUPERNUS PHARMACEUTICALS, INC. Filed: 2025-06-16 AccNo: 0001104659-25-059687 Size: 5 MB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits